Healthcare / Drug Manufacturers - Specialty & GenericIstanbul
$65.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.5B · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.0B
P/E
N/A
•EV/EBITDA
4.0x
↓ROE
-3.1%
↓Gross Margin
32.8%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+30.2%
FCF CAGR
—
FCF margin
15.2%
FCF / Net income
-3.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.25B · net income $-807.0M · FCF $2.92B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.25B | $19.25B | $20.23B | $16.36B | $8.71B |
| Net Income | $-807.0M | $-807.0M | $90.9M | $4.89B | $851.1M |
| EBITDA | $4.19B | $4.19B | $5.69B | $6.03B | $3.05B |
| EPS | -4.03 | -4.03 | 0.45 | 24.44 | 4.26 |
| Gross Margin | 32.8% | 32.8% | 39.9% | 41.9% | 33.1% |
| Operating Margin | 0.0% | 0.0% | 10.9% | 9.7% | 1.3% |
| Net Margin | -4.2% | -4.2% | 0.4% | 29.9% | 9.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.30 | 0.37 | 0.49 |
| Current Ratio | 2.00 | 2.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.92B | $2.92B | $5.65B | $3.47B | $-42.8M |
| Returns | |||||
| ROE | -3.1% | -3.1% | 0.3% | 22.9% | 7.4% |
| Valuation | |||||
| P/E | — | — | 174.78 | 3.28 | 14.11 |
| EV/EBITDA | 3.96 | 3.96 | 3.96 | 3.61 | 5.45 |
| P/B | 0.49 | 0.49 | 0.58 | 0.75 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | -4.9% | -4.9% | 23.7% | 87.8% | — |
| EPS Growth | -995.6% | -995.6% | -98.2% | 473.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.45 → -4.03
Residual
+18.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.